A Phase 4 interventional study of Oasis in Tinnitus and Hyperacusis, sponsored by Neuromonics, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-25.
Sponsored by Neuromonics, Inc. · Phase 4, Interventional, and Treatment
Neuromonics TInnitus Treatment CALM study is a multi site study of 100 adult subjects with clinically significant disturbing tinnitus to evaluate outcome measures using the FDA cleared Neuromonics treatment after 6, 12, 24 and 36 months. Patients must be meet certain inclusion criteria and they are also required to pay for the all costs of the treatment. Subjects will be provided a modest participation fee at 6, 12, 24 and 36 months upon completion of patient questionnaires (subjects must have access to a computer and internet in order to complete on line questionnaires).
444 studies on the registry are indexed under Tinnitus; 98 are open to participants now.
This study's enrollment of 53 is below the median of 60 across 368 interventional studies indexed under Tinnitus.
Browse Tinnitus studies →This is the only study on the registry with Neuromonics, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
Also known as: Neuromonics Oasis Tinnitus Treatment
Pre and post treatment scores on Tinnitus reaction questionnaire
Time frame: 6, 12, 24, 36 months
Tinnitus Handicap Inventory, Hospital Anxiety and Depression Scale,
Time frame: 6, 12, 24, 36 months
This study is status unknown, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.